OncoAlert Horizons
OncoAlert’s educational series: two experts on one evolving question in practice, a focus at a time.
On the stage: Adjuvant treatment challenges in early HR+/HER2− breast cancer: the emerging role of next-generation oral SERDs
Dr. Sibylle Loibl and Dr. Rupert Bartsch
June 15, 2026. 14 minutes.
Supported by an unrestricted educational grant from Roche. All content was independently developed and fully controlled by the faculty.
Breast cancer
Discussions on breast cancer, newest first.
Adjuvant treatment challenges in early HR+/HER2− breast cancer: the emerging role of next-generation oral SERDs
Dr. Sibylle Loibl and Dr. Rupert Bartsch
June 15, 2026. 14 minutes.
On the stage
The new sequencing challenge in HER2+ metastatic breast cancer
Dr. Javier Cortés and Dr. Elisa Agostinetto
June 10, 2026. 17 minutes.
Early HER2+ breast cancer: escalate, de-escalate or personalize?
Dr. Giampaolo Bianchini and Dr. François-Clément Bidard
May 26, 2026. 20 minutes.
What comes after CDK4/6 inhibitors? SERDs, combinations and the future of HR+ advanced breast cancer
Dr. Sherene Loi and Dr. Elisa Agostinetto
May 20, 2026. 14 minutes.